About Shire Human Genetic
Therapies, Inc. (HGT)

Shire HGT, a business unit of global specialty biopharmaceutical company Shire plc, is committed to collaborating with academic researchers, health care professionals, and patient associations around the world.

Our shared goal is a deeper understanding of life-altering genetic disorders. Our work together includes the investigation and development of therapeutic approaches in rare genetic diseases.

For more information about Shire, visit our corporate Web site at www.shire.com.

OnePathSM is a comprehensive and individualized product support system dedicated to helping patients, families, and healthcare providers. The array of services offered by OnePathSM provides assistance for eligible US patients in accessing therapy.

OnePath; The way to care

If you are a physician and interested in finding out more about how OnePathSM can help you and your patients, please contact our OnePath services at 1-866-888-0660.

For more information

Request Updates

Get updates by email:


 

June 22, 2010

Due to the accelerated approval for VPRIVTM (velaglucerase alfa for injection) and early access programs we initiated for patients during the continuing imiglucerase supply shortage, as well as the extremely high demand for VPRIV that has followed, we must now closely monitor future demand, inventory and capacity in order to set appropriate expectations for additional patients that may be interested in VPRIV in the future.

The purpose of this letter is to emphasize that for patients who are currently on VPRIV or already in the process to begin VPRIV therapy (i.e. Shire has received a OnePathSM start form), nothing has changed. We can tell you that we are committed to ensuring patients currently on VPRIV will continue to have uninterrupted access to treatment at their prescribed dose. We also want to assure you we have sufficient inventory to meet the expected demand of all patients for whom a start form has been submitted and received by Shire by June 21, 2010.

To ensure continued access to all patients mentioned above, we need to carefully manage additional requests for VPRIV. Therefore, for additional patients who submit a start form after June 21, 2010, Shire has established a waiting list process. Patients will be added to the list according to the date Shire receives their start form. This waitlist will enable patients to begin the process of accessing treatment as soon as additional product becomes available.

We are working to optimize our existing manufacturing facilities to increase supply, and are expanding manufacturing facilities by building a new production site in Lexington, MA (USA).

Finally, we would like to reassure you that this process has nothing to do with product quality or manufacturing delays or concerns. Rather, it is centered on an accelerated launch timeline, finite capacity, and extremely high demand.

If you should have further questions, please contact OnePathSM. OnePathSM, our comprehensive U.S. product support center, is available from 8:30am to 8:00pm (ET) at 1-866-888-0660 and can assist with any questions you may have as well.

View announcement archives

Ask Shire

Questions about Treatment?
Ask Shire.
We'd like to give you this opportunity to ask questions, share concerns, and provide comments about treatment. A Shire representative will call you to respond.

Ask Shire »